# Michael Staehler

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/michael-staehler/

## Facts

| Field | Value |
| --- | --- |
| Citations | 22,786 |
| Field | Renal cell carcinoma treatment |
| h-index | 65 |
| i10-index | 169 |
| Last Known Institution | München Klinik |
| OpenAlex ID | https://openalex.org/A5091833311 |
| ORCID iD | https://orcid.org/0000-0002-4574-6522 |
| Works | 485 |

## Researcher papers

- [Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma](https://scholariq.org/papers/pazopanib-versus-sunitinib-in-metastatic-renal-cell-carcinoma/)
- [Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial](https://scholariq.org/papers/adjuvant-nivolumab-plus-ipilimumab-versus-placebo-for-localised-renal-cell/)
- [Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study](https://scholariq.org/papers/lenvatinib-plus-pembrolizumab-versus-sunitinib-as-first-line-treatment-of/)

## Researcher topics

- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)
- [Renal and related cancers](https://scholariq.org/topics/renal-and-related-cancers/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Bladder and Urothelial Cancer Treatments](https://scholariq.org/topics/bladder-and-urothelial-cancer-treatments/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Researcher university

- [München Klinik](https://scholariq.org/institutions/munchen-klinik/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.